Advertisement

Journal of Neurology

, Volume 265, Issue 2, pp 239–252 | Cite as

Low intrathecal antibody production despite high seroprevalence of Epstein–Barr virus in multiple sclerosis: a review of the literature

  • Klemens Ruprecht
  • Brigitte Wildemann
  • Sven Jarius
Review

Abstract

Background

Patients with multiple sclerosis (MS) frequently have an intrathecal production of antibodies to different common viruses, which can be detected by elevated antiviral antibody indices (AIs). There is a strong and consistent association of MS and Epstein–Barr virus (EBV) infection.

Objective

To systematically compare the frequencies of intrathecal antibody production to EBV, measles virus, rubella virus, varicella zoster virus (VZV) and herpes simplex virus (HSV) in patients with MS.

Methods

Review of the English and German literature on the frequencies of intrathecal immunoglobulin (Ig)G antibody production, as defined by an elevated AI, to EBV, measles virus, rubella virus, VZV and HSV in adult and pediatric patients with MS.

Results

In nine original studies identified, the frequencies of an intrathecal production of antibodies to Epstein–Barr nuclear antigen-1 (33/340, 9.7%), EBV viral capsid antigen (12/279, 4.3%) and antigens from EBV-infected cell lines (14/90, 15.6%) in adult patients with MS were clearly lower (p ≤ 0.03 for all pairwise comparisons) than the frequencies of an intrathecal production of antibodies to measles virus (612/922, 66.4%), rubella virus (521/922, 56.5%), VZV (470/922, 51%; data from 17 original studies) and HSV (78/291, 26.8%; data from 6 original studies). Though based on a lower number of original studies and patients, findings in children with MS were essentially similar. As in adults and children with MS the seroprevalence of EBV is higher than the seroprevalences of the other investigated viruses, the lower frequency of elevated EBV AIs became even more pronounced after correction of the frequencies of elevated antiviral AIs for the seroprevalences of the respective viruses.

Conclusions

Given the very high seroprevalence of EBV in MS, the frequency of intrathecally produced antibodies to EBV in patients with MS is paradoxically low compared to that of other common viruses. These findings are compatible with the recently proposed hypothesis that in individuals going on to develop MS antiviral antibody-producing cells may invade the brain predominantly at the time of and triggered by acute primary EBV infection, before anti-EBV IgG producing cells have yet occurred.

Keywords

Multiple sclerosis Epstein–Barr virus Measles virus Rubella virus Varicella zoster virus Herpes simplex virus Antibodies Antibody index Cerebrospinal fluid Serum Seroprevalence Children 

Notes

Acknowledgements

This work was supported by the German Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis) and the Charité Research Fund. BW and SJ are thankful to the Dietmar Hopp Stiftung, Germany, and to Merck Serono, Germany, for funding research on the role of antibodies in the differential diagnosis of multiple sclerosis at the Department of Neurology, University Hospital Heidelberg, Germany.

Author contributions

KR conceived of the study, collected and analysed data, and wrote the manuscript. SJ and BW collected and analysed data and critically revised the manuscript. All authors read and approved the final manuscript.

Compliance with ethical standards

Conflicts of interest

KR was supported by the German Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis) and has received research support from Novartis and Merck Serono as well as speaking fees or travel grants from Guthy Jackson Charitable Foundation, Bayer Healthcare, Biogen Idec, Merck Serono, sanofi-aventis/Genzyme, Teva Pharmaceuticals, Roche and Novartis. BW received grants from the German Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis), Dietmar Hopp Foundation and Klaus Tschira Foundation, grants and personal fees from Biogen, Merck Serono, Sanofi Genzyme, Novartis pharmaceuticals, Teva Pharma and personal fees from Bayer Healthcare. SJ reports no conflicts of interest.

References

  1. 1.
    Almohmeed YH, Avenell A, Aucott L, Vickers MA (2013) Systematic review and meta-analysis of the sero-epidemiological association between Epstein Barr virus and multiple sclerosis. PLoS One 8:e61110CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Alotaibi S, Kennedy J, Tellier R, Stephens D, Banwell B (2004) Epstein–Barr virus in pediatric multiple sclerosis. JAMA 291:1875–1879CrossRefPubMedGoogle Scholar
  3. 3.
    Ascherio A, Munger KL (2007) Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 61:288–299CrossRefPubMedGoogle Scholar
  4. 4.
    Ascherio A, Munger KL (2016) Epidemiology of multiple sclerosis: from risk factors to prevention—an update. Semin Neurol 36:103–114CrossRefPubMedGoogle Scholar
  5. 5.
    Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernan MA, Olek MJ, Hankinson SE, Hunter DJ (2001) Epstein–Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 286:3083–3088CrossRefPubMedGoogle Scholar
  6. 6.
    Ascherio A, Munger KL, Lunemann JD (2012) The initiation and prevention of multiple sclerosis. Nat Rev Neurol 8:602–612CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Balfour HH Jr, Odumade OA, Schmeling DO, Mullan BD, Ed JA, Knight JA, Vezina HE, Thomas W, Hogquist KA (2013) Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J Infect Dis 207:80–88CrossRefPubMedGoogle Scholar
  8. 8.
    Banwell B, Krupp L, Kennedy J, Tellier R, Tenembaum S, Ness J, Belman A, Boiko A, Bykova O, Waubant E, Mah JK, Stoian C, Kremenchutzky M, Bardini MR, Ruggieri M, Rensel M, Hahn J, Weinstock-Guttman B, Yeh EA, Farrell K, Freedman M, Iivanainen M, Sevon M, Bhan V, Dilenge ME, Stephens D, Bar-Or A (2007) Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 6:773–781CrossRefPubMedGoogle Scholar
  9. 9.
    Bednarova J, Stourac P, Adam P (2005) Relevance of immunological variables in neuroborreliosis and multiple sclerosis. Acta Neurol Scand 112:97–102CrossRefPubMedGoogle Scholar
  10. 10.
    Belbasis L, Bellou V, Evangelou E, Ioannidis JP, Tzoulaki I (2015) Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol 14:263–273CrossRefPubMedGoogle Scholar
  11. 11.
    Brettschneider J, Tumani H, Kiechle U, Muche R, Richards G, Lehmensiek V, Ludolph AC, Otto M (2009) IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. PLoS One 4:e7638CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Castellazzi M, Contini C, Tamborino C, Fasolo F, Roversi G, Seraceni S, Rizzo R, Baldi E, Tola MR, Bellini T, Granieri E, Fainardi E (2014) Epstein–Barr virus-specific intrathecal oligoclonal IgG production in relapsing-remitting multiple sclerosis is limited to a subset of patients and is composed of low-affinity antibodies. J Neuroinflammation 11:188CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Castellazzi M, Tamborino C, Cani A, Negri E, Baldi E, Seraceni S, Tola MR, Granieri E, Contini C, Fainardi E (2010) Epstein–Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis. Mult Scler 16:883–887CrossRefPubMedGoogle Scholar
  14. 14.
    Compston A, Coles A (2008) Multiple sclerosis. Lancet 372:1502–1517CrossRefPubMedGoogle Scholar
  15. 15.
    Delorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelman JH, Ascherio A (2006) Epstein–Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol 63:839–844CrossRefPubMedGoogle Scholar
  16. 16.
    Denne C, Kleines M, Dieckhofer A, Ritter K, Scheithauer S, Merz U, Hausler M (2007) Intrathecal synthesis of anti-viral antibodies in pediatric patients. Eur J Paediatr Neurol 11:29–34CrossRefPubMedGoogle Scholar
  17. 17.
    Felgenhauer K, Reiber H (1992) The diagnostic significance of antibody specificity indices in multiple sclerosis and herpes virus induced diseases of the nervous system. Clin Investig 70:28–37CrossRefPubMedGoogle Scholar
  18. 18.
    Goodin DS (2009) The causal cascade to multiple sclerosis: a model for MS pathogenesis. PLoS One 4:e4565CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Graef IT, Henze T, Reiber H (1994) Polyspecific immune reaction in the central nervous system in autoimmune diseases with CNS involvement. Z Arztl Fortbild Jena 88:587–591PubMedGoogle Scholar
  20. 20.
    Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, Ramagopalan SV (2010) An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS One 5:e12496CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Hottenrott T, Dersch R, Berger B, Rauer S, Huzly D, Stich O (2017) The MRZ reaction in primary progressive multiple sclerosis. Fluids Barriers CNS 14:2CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Jacobi C, Lange P, Reiber H (2007) Quantitation of intrathecal antibodies in cerebrospinal fluid of subacute sclerosing panencephalitis, herpes simplex encephalitis and multiple sclerosis: discrimination between microorganism-driven and polyspecific immune response. J Neuroimmunol 187:139–146CrossRefPubMedGoogle Scholar
  23. 23.
    Jarius S, Eichhorn P, Franciotta D, Petereit HF, Akman-Demir G, Wick M, Wildemann B (2017) The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. J Neurol 264:453–466CrossRefPubMedGoogle Scholar
  24. 24.
    Jarius S, Franciotta D, Bergamaschi R, Rauer S, Wandinger KP, Petereit HF, Maurer M, Tumani H, Vincent A, Eichhorn P, Wildemann B, Wick M, Voltz R (2008) Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry 79:1134–1136CrossRefPubMedGoogle Scholar
  25. 25.
    Krone B, Pohl D, Rostasy K, Kahler E, Brunner E, Oeffner F, Grange JM, Gartner J, Hanefeld F (2008) Common infectious agents in multiple sclerosis: a case–control study in children. Mult Scler 14:136–139CrossRefPubMedGoogle Scholar
  26. 26.
    Levin LI, Munger KL, O’Reilly EJ, Falk KI, Ascherio A (2010) Primary infection with the Epstein–Barr virus and risk of multiple sclerosis. Ann Neurol 67:824–830PubMedPubMedCentralGoogle Scholar
  27. 27.
    Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET, Spiegelman D, Ascherio A (2005) Temporal relationship between elevation of Epstein–Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 293:2496–2500CrossRefPubMedGoogle Scholar
  28. 28.
    Makhani N, Banwell B, Tellier R, Yea C, McGovern S, O’Mahony J, Ahorro JM, Arnold D, Sadovnick AD, Marrie RA, Bar-Or A (2016) Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination. Mult Scler 22:385–388CrossRefPubMedGoogle Scholar
  29. 29.
    Munger KL, Levin LI, O’Reilly EJ, Falk KI, Ascherio A (2011) Anti-Epstein–Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult Scler 17:1185–1193CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Otto C, Hofmann J, Ruprecht K (2016) Antibody producing B lineage cells invade the central nervous system predominantly at the time of and triggered by acute Epstein–Barr virus infection: a hypothesis on the origin of intrathecal immunoglobulin synthesis in multiple sclerosis. Med Hypotheses 91:109–113CrossRefPubMedGoogle Scholar
  31. 31.
    Otto C, Oltmann A, Stein A, Frenzel K, Schroeter J, Habbel P, Gartner B, Hofmann J, Ruprecht K (2011) Intrathecal EBV antibodies are part of the polyspecific immune response in multiple sclerosis. Neurology 76:1316–1321CrossRefPubMedGoogle Scholar
  32. 32.
    Pakpoor J, Disanto G, Gerber JE, Dobson R, Meier UC, Giovannoni G, Ramagopalan SV (2012) The risk of developing multiple sclerosis in individuals seronegative for Epstein–Barr virus: a meta-analysis. Mult Scler 19:162–166CrossRefPubMedGoogle Scholar
  33. 33.
    Pebody RG, Andrews N, Brown D, Gopal R, De Melker H, Francois G, Gatcheva N, Hellenbrand W, Jokinen S, Klavs I, Kojouharova M, Kortbeek T, Kriz B, Prosenc K, Roubalova K, Teocharov P, Thierfelder W, Valle M, Van Damme P, Vranckx R (2004) The seroepidemiology of herpes simplex virus type 1 and 2 in Europe. Sex Transm Infect 80:185–191CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Petereit HF, Reske D (2005) Expansion of antibody reactivity in the cerebrospinal fluid of multiple sclerosis patients—follow-up and clinical implications. Cerebrospinal Fluid Res 2:3CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Pfuhl C, Oechtering J, Rasche L, Giess RM, Behrens JR, Wakonig K, Freitag E, Pache FC, Otto C, Hofmann J, Eberspacher B, Bellmann-Strobl J, Paul F, Ruprecht K (2015) Association of serum Epstein–Barr nuclear antigen-1 antibodies and intrathecal immunoglobulin synthesis in early multiple sclerosis. J Neuroimmunol 285:156–160CrossRefPubMedGoogle Scholar
  36. 36.
    Poethko-Muller C, Mankertz A (2012) Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity. PLoS One 7:e42867CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Pohl D, Krone B, Rostasy K, Kahler E, Brunner E, Lehnert M, Wagner H-J, Gärtner J, Hanefeld F (2006) High seroprevalence of Epstein–Barr virus in children with multiple sclerosis. Neurology 67:2063–2065CrossRefPubMedGoogle Scholar
  38. 38.
    Pohl D, Rostasy K, Jacobi C, Lange P, Nau R, Krone B, Hanefeld F (2009) Intrathecal antibody production against Epstein–Barr and other neurotropic viruses in pediatric and adult onset multiple sclerosis. J Neurol 257:212–216CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Puccioni-Sohler M, Kitze B, Felgenhauer K, Graef IT, Lange P, Novis S, Reiber H, Vaz B (1995) The value of CSF analysis for the differential diagnosis of HTLV-I associated myelopathy and multiple sclerosis. Arq Neuropsiquiatr 53:760–765CrossRefPubMedGoogle Scholar
  40. 40.
    Rand KH, Houck H, Denslow ND, Heilman KM (2000) Epstein–Barr virus nuclear antigen-1 (EBNA-1) associated oligoclonal bands in patients with multiple sclerosis. J Neurol Sci 173:32–39CrossRefPubMedGoogle Scholar
  41. 41.
    Reiber H (2017) Polyspecific antibodies without persisting antigen in multiple sclerosis, neurolupus and Guillain–Barre syndrome: immune network connectivity in chronic diseases. Arq Neuropsiquiatr 75:580–588CrossRefPubMedGoogle Scholar
  42. 42.
    Reiber H, Kruse-Sauter H, Quentin CD (2015) Antibody patterns vary arbitrarily between cerebrospinal fluid and aqueous humor of the individual multiple sclerosis patient: specificity-independent pathological B cell function. J Neuroimmunol 278:247–254CrossRefPubMedGoogle Scholar
  43. 43.
    Reiber H, Lange P (1991) Quantification of virus-specific antibodies in cerebrospinal fluid and serum: sensitive and specific detection of antibody synthesis in brain. Clin Chem 37:1153–1160PubMedGoogle Scholar
  44. 44.
    Reiber H, Peter JB (2001) Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci 184:101–122CrossRefPubMedGoogle Scholar
  45. 45.
    Reiber H, Teut M, Pohl D, Rostasy KM, Hanefeld F (2009) Paediatric and adult multiple sclerosis: age-related differences and time course of the neuroimmunological response in cerebrospinal fluid. Mult Scler 15:1466–1480CrossRefPubMedGoogle Scholar
  46. 46.
    Reiber H, Ungefehr S, Jacobi C (1998) The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler 4:111–117CrossRefPubMedGoogle Scholar
  47. 47.
    Rickinson AB, Kieff E (2001) Epstein–Barr virus. In: Knipe DM, Howley PM (eds) Virology. Lippincott Williams and Wilkins, New York, pp 2575–2627Google Scholar
  48. 48.
    Robinson-Agramonte M, Reiber H, Cabrera-Gomez JA, Galvizu R (2007) Intrathecal polyspecific immune response to neurotropic viruses in multiple sclerosis: a comparative report from Cuban patients. Acta Neurol Scand 115:312–318CrossRefPubMedGoogle Scholar
  49. 49.
    Rosche B, Laurent S, Conradi S, Hofmann J, Ruprecht K, Harms L (2012) Measles IgG antibody index correlates with T2 lesion load on MRI in patients with early multiple sclerosis. PLoS One 7:e28094CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Rostasy K, Reiber H, Pohl D, Lange P, Ohlenbusch A, Eiffert H, Maass M, Hanefeld F (2003) Chlamydia pneumoniae in children with MS: frequency and quantity of intrathecal antibodies. Neurology 61:125–128CrossRefPubMedGoogle Scholar
  51. 51.
    Sargsyan SA, Shearer AJ, Ritchie AM, Burgoon MP, Anderson S, Hemmer B, Stadelmann C, Gattenlohner S, Owens GP, Gilden D, Bennett JL (2010) Absence of Epstein–Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology 74:1127–1135CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Schubert J, Weissbrich B (2007) Detection of virus-specific intrathecally synthesised immunoglobulin G with a fully automated enzyme immunoassay system. BMC Neurol 7:12CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Sindic CJ, Monteyne P, Laterre EC (1994) The intrathecal synthesis of virus-specific oligoclonal IgG in multiple sclerosis. J Neuroimmunol 54:75–80CrossRefPubMedGoogle Scholar
  54. 54.
    Sisay S, Lopez-Lozano L, Mickunas M, Quiroga-Fernandez A, Palace J, Warnes G, Alvarez-Lafuente R, Dua P, Meier UC (2017) Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS. J Neuroimmunol 306:40–45CrossRefPubMedGoogle Scholar
  55. 55.
    Sundstrom P, Juto P, Wadell G, Hallmans G, Svenningsson A, Nystrom L, Dillner J, Forsgren L (2004) An altered immune response to Epstein–Barr virus in multiple sclerosis: a prospective study. Neurology 62:2277–2282CrossRefPubMedGoogle Scholar
  56. 56.
    Thorley-Lawson DA (2005) EBV persistence and latent infection in vivo. In: Robertson ES (ed) Epstein–Barr virus. Caister Academic Press, Wymondham, pp 309–358Google Scholar
  57. 57.
    Villegas E, Santiago O, Carrillo JA, Sorlozano A, Guerrero M, Fernandez O, Gutierrez J (2011) Low intrathecal immune response of anti-EBNA-1 antibodies and EBV DNA from multiple sclerosis patients. Diagn Microbiol Infect Dis 70:85–90CrossRefPubMedGoogle Scholar
  58. 58.
    Waubant E, Mowry EM, Krupp L, Chitnis T, Yeh EA, Kuntz N, Ness J, Chabas D, Strober J, McDonald J, Belman A, Milazzo M, Gorman M, Weinstock-Guttman B, Rodriguez M, Oksenberg JR, James JA (2011) Common viruses associated with lower pediatric multiple sclerosis risk. Neurology 76:1989–1995CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Department of NeurologyCharité - Universitätsmedizin BerlinBerlinGermany
  2. 2.Clinical and Experimental Multiple Sclerosis Research CenterCharité - Universitätsmedizin BerlinBerlinGermany
  3. 3.Molecular Neuroimmunology Group, Department of NeurologyUniversity of HeidelbergHeidelbergGermany

Personalised recommendations